Le Méridien Vaccine (06660) issued an announcement. The board of directors of the company received a notice from Zhou Yan (Chairman of the Board of Directors, Executive Director, CEO and controlling shareholder of the Company) that Zhou Yan will continue to further increase the company's H shares (“this increase”) through the open market from January 12, 2024 to April 15, 2024. From November 14, 2023 to April 15, 2024, Zhou Yan has continued to increase her H shares in the company with a total of HK$10,420,212.00 through the open market, and it is not ruled out that she will continue to increase her shares in due course.
As of the date of this announcement, the company's operations, finance, and sales of existing products were normal, and vaccine research and development in the research pipeline progressed normally according to the plan. The board of directors believes that Zhou Yan's continuous increase in the company's shares with his own capital is a judgment based on the company's intrinsic value and future growth potential, which shows his confidence and recognition of the company's future development and is conducive to the implementation of the company's long-term strategic layout.